Original Article |
|
Corresponding author: Zeynel Abidin Sayiner ( zeynelasayiner@hotmail.com ) © 2025 Zekiye Büşra Şahin, Zeynel Abidin Sayiner, Ersin Akarsu.
This is an open access article distributed under the terms of the Creative Commons Attribution License (CC BY 4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Citation:
Şahin ZB, Sayiner ZA, Akarsu E (2025) The effect of the presence of Hashimoto’s thyroiditis on the frequency of papillary thyroid carcinoma subtypes. Folia Medica 67(1): e138135. https://doi.org/10.3897/folmed.67.e138135
|
Aim: Papillary thyroid carcinoma (PTC) subtypes are known to differ from each other in terms of the features associated with each subtype. The aim of this study was to determine whether the incidence of PTC subtypes differs in the presence or absence of Hashimoto’s thyroiditis.
Materials and methods: A total of 1195 patients were included and evaluated for the presence of nodules, divided into two groups: those with Hashimoto’s thyroiditis and thyroid nodules (HT) and those with thyroid nodules only (non-HT). The two groups were compared with respect to demographics, clinical, ultrasonographic and cytological characteristics of thyroid nodules, and the presence of PTC.
Results: Of the patients, 943 (78.9%) were diagnosed with thyroid nodules without HT (non-HT group) and 252 (21.1%) with thyroid nodules with HT (HT group). The incidence of indeterminate cytology (Bethesda category III) was significantly higher in the HT group than in the non-HT group (18.60% vs. 10.80%, p=0.001). The incidence of PTC was also statistically significantly higher in the HT group than in the non-HT group (22.2% vs. 5.7%, p=0.001). However, no correlation was observed between the histopathological subtypes of PTC and the presence of Hashimoto’s thyroiditis.
Conclusion: Hashimoto’s thyroiditis did not appear to alter the incidence of PTC subtypes. However, PTC was more frequently observed in thyroid nodules associated with HT compared to those without HT.
Hashimoto thyroiditis, papillary thyroid carcinoma, thyroid nodule
Recent studies have suggested that lymphocytic infiltration and immunological factors observed in Hashimoto’s thyroiditis (HT) may lead to an increased risk of developing papillary thyroid cancer. HT is the most common autoimmune thyroid disease, affecting 2%–15% of the world’s population, and the most common cause of hypothyroidism.[
The aims of this study were to determine the clinical, sonographic, and cytological findings in patients with thyroid nodules with HT, whether there is a difference from the findings in patients with thyroid nodules without HT diagnosis, and whether there is an association between PTC risk and PTC subtypes in the presence of HT and thyroid nodules.
In this retrospective study, patients who were treated at the Department of Endocrinology and Metabolism at Gaziantep University Medical School were diagnosed with nodular thyroid disease and underwent fine needle aspiration biopsy of thyroid nodules. The study was approved by the decision of the Clinical Research Ethics Committee. Patients aged 18-80 were included in the study. Patients taking anti-thyroid drugs, patients who had previously received radioactive iodine (to rule out Graves’ disease), patients who had received radiotherapy to the head and neck, and patients who had taken drugs (glucocorticoids, lithium, etc.) that could affect thyroid function were excluded from the study. Thus, 1195 patients were included in the study. The decision to proceed with surgery was based on the results of the nodule cytology, the detection of compression findings and the expressed preference of the patient. The findings were obtained by retrospective collection of data regarding the characteristics of the nodules that were histopathologically confirmed as papillary thyroid carcinoma or noninvasive follicular thyroid neoplasm with papillary-like nuclear features (NIFT-P)
The age, sex, history of radiotherapy to the neck region, history of additional cancer, history of previous thyroid surgery, and history of thyroid cancer in first-degree relatives of the patients were examined. The free triiodothyronine (fT3), free thyroxine (fT4), thyroid stimulating hormone (TSH), and anti-thyroid peroxidase (anti-TPO) levels in the 6 months prior to fine needle aspiration biopsy (FNAB) were recorded as the data closest to the biopsy date.
The diagnosis of HT was made based on the following two criteria:
The patients were evaluated in two groups: HT and non-HT. Demographic data (age and sex), sonographic features of the thyroid gland and thyroid nodules, and nodule cytology features of patients in both groups were compared. Cytological and histological parameters were based on a report review only. The number of thyroid cancers was compared between the two groups. Age, sex, and PTC pathological findings, which were the most common thyroid cancers in both groups, were compared.
The pathological parameters evaluated included tumor diameter (cm), lymph node invasion (yes or no), vascular invasion (yes or no), distant metastasis (yes or no), extrathyroidal involvement (present or absent), multifocal involvement, histopathological reports, PTC subtype (follicular, classical, tall cell, NIFTY, trabecular subtype, insular, oncocytic, or hobnail cell subtype), and presence of concomitant chronic lymphocytic thyroiditis.
The conformity of the numerical variables to the normal distribution was tested using the Shapiro-Wilk test. Mann Whitney U test was used to compare the non-normally distributed variables in two groups. The chi-square test was used to test the relationships between categorical variables. Numerical variables were indicated by means and standard deviations, and categorical variables were presented as numbers and percentages. The SPSS 22.0, Windows version package program was used in the analysis. Statistical significance was set at p<0.05.
The study included 1195 patients. Of these, 943 (78.9%) were in the group with thyroid nodules without HT (non-HT group) and 252 (21.1%) were in the group with thyroid nodules with HT (HT group). The age, sex, history of radiotherapy to the neck region, history of additional cancer, history of previous thyroid surgery, and history of thyroid cancer in first-degree relatives of the patients were examined. These variables were similar in both groups, except for the TSH values. TSH levels were higher in the HT group than in the non-HT group, and those with high TSH values had more total thyroidectomies (p<0.001) (Table
There was no statistical difference between the patient groups in preoperative thyroid ultrasound evaluation according to TIRADS classification (p>0.05). The distribution of nodule cytology according to Bethesda classification of patients in the non-HT and HT groups is shown in Table
The incidence of histopathologically proven PTC was found to be statistically significantly higher in the HT group than in the non-HT group (HT and non-HT: 22.2% vs. 5.7%, p=0.001). PTC was observed in only two patients classified under Bethesda category II. The two individuals under consideration were assigned to the HT cohort. PTC was observed in 1.8% (2/107) of patients who exhibited benign cytology (Table
There was no statistically significant difference between the incidence of PTC subtypes in the HT and non-HT groups (p=0.990). The most common papillary thyroid carcinoma subtype was follicular thyroid carcinoma in both groups (Table
Sonographic nodule characteristics in patients with PTC were compared between the two groups, and no statistical significance was found (p>0.05) (Table
The prognostic pathological features of PTC in both groups were compared. No statistically significant differences were found in lymph node invasion, vascular invasion, extrathyroidal involvement, multifocal involvement, and tumor size, which are considered prognostic variables.
| Parameters | Groups | P values | |||
| Non-HT | HT | ||||
| Count | Mean | Count | Mean | ||
| Age (years) | 943 | 47±13 | 252 | 46±13 | 0.688 |
| TSH (mU/mL) | 943 | 1.50±2.07 | 252 | 2.24±2.42 | 0.001* |
| Free T3 (ng/dl) | 943 | 0.89±0.17 | 252 | 0.87±0.19 | 0.687 |
| Free T4 (μg/dl) | 943 | 3.67±0.53 | 252 | 3.67±0.57 | 0.677 |
| Nodule diameter (cm) | 943 | 2.7±1.1 | 252 | 2.7±1.3 | 0.766 |
| Tumor diameter (cm) | 52 | 1.73±1.49 | 56 | 1.67±1.50 | 0.753 |
Distribution of nodule cytology according to Bethesda classification of patients and the frequency of histopathologically proven PTC of patients in non-HT and HT groups
| Nodule cytology | Non-HT n (%) | HT n (%) | P |
| Benign | 548 (58.1) | 107 (42.5) | 0.001* |
| Atypia of undetermined significance | 70 (7.4) | 26 (10.3) | 0.122 |
| Follicular neoplasm/suspicious for follicular neoplasm | 8 (0.8) | 2 (0.8) | 0.990 |
| Suspicious for malignancy | 18 (1.9) | 19 (7.5) | 0.001* |
| Malignant | 16 (1.7) | 7 (2.8) | 0.236 |
| Non diagnostic/unsatisfactory | 252 (26.7) | 82 (32.5) | 0.540 |
| Histopathologically proven papillary thyroid carcinoma | 54 (5.7) | 56 (22.2) | 0.001* |
| Papillary thyroid carcinoma subtypes | Non-HT group n (%) | HT group n (%) | P values |
| Follicular | 26 (50.0) | 29 (52.7) | 0.85 |
| Classical | 10 (19.2) | 10 (18.2) | 0.99 |
| Tall cell | 7 (13.5) | 7 (12.7) | 0.99 |
| NIFTP | 4 (7.7) | 3 (5.5) | 0.87 |
| Trabecular | 2 (3.8) | 1 (1.8) | 0.89 |
| Hobnail | 1 (1.9) | 1 (1.8) | 0.99 |
| Insular | 1 (1.9) | 2 (3.6) | 0.86 |
| Non-HT n (%) | HT n (%) | P | |
| Nodule echogenicity | 0.569 | ||
| Hypoechoic | 11 (20.4) | 11 (19.6) | |
| Hyperechoic | 1 (1.9) | 2 (3.6) | |
| Mixechoic | 39 (72.2) | 36 (64.3) | |
| Isoechoic | 3 (5.6) | 7 (12.5) | |
| Margin irregularity presence | 14 (25.9) | 13 (23.2) | 0.741 |
| Microcalcification | 6 (11.1) | 5 (8.9) | 0.703 |
| Solidity | 1 (1.9) | 1 (1.8) | 0.979 |
| Nodule diameter | 0.765 | ||
| <2 cm | 33 (63.5) | 38 (67.9) | |
| 2-4 cm | 15 (28.8) | 13 (23.2) | |
| >4 cm | 4 (7.7) | 5 (8.9) |
Thyroid nodules are a common condition. The frequency of thyroid nodules in autopsy results of individuals without known thyroid disease was found to be 50%, and this rate varies between 19% and 67% in ultrasound scans of healthy individuals.[
In our study, no difference was found in terms of cytological diagnosis of malignancy between the HT and non-HT groups (2.8% vs. 1.7%, p=0.236). In a study conducted by Matesa-Anić et al. from Croatia, the FNAB of 10508 consecutive patients who were treated at the outpatient clinic was analyzed. While the prevalence of PTC in patients with HT was 1.9%, the prevalence of PTC in patients without HT was 2.7%; no significant relationship was found between HT and PTC in this study.[
In a study by Ohmori et al., in which US features of papillary thyroid cancer were compared between patients with and without HT, many US features were reported to be similar.[
Many studies have emphasized that HT is a protective factor against poor prognosis in PTC. It is argued that the immune response, which occurs especially on the basis of HT or chronic lymphocytic thyroiditis and causes destruction of the thyroid parenchyma, also destroys tumoral cells in the same way, thus partially inhibiting tumor spread; ultimately, the tumor has a less aggressive course.[
Our study had several limitations. First, we studied patients retrospectively; therefore, our results cannot be generalized to the general population and do not reflect large-scale epidemiological data on HT or thyroid cancer. Second, confounding variables may have influenced our results. Detection of mutations in PTC cells: as the current research is a retrospective study and real-time evaluation of ultrasonography findings is impossible, the findings cannot be evaluated in real time. Therefore, the interpretation may vary between operators. However, this limitation does not diminish the significance of this investigation, as all preoperative sonograms were interpreted by two experienced endocrinologists.
In conclusion, the relationship between HT and thyroid cancer remains controversial, despite numerous studies. In our study, PTC was found to be significantly more common in nodules with Hashimoto thyroiditis. In thyroid nodule evaluation, Hashimoto’s disease does not seem to affect papillary thyroid carcinoma subtypes. In addition, the presence of HT in the ultrasonographic features of thyroid nodules did not seem to affect the frequency of PTC diagnoses.
E.A., Z.A.S., and Z.B.Ş. gathered and analyzed data; Z.A.S. wrote the article; Z.A.S. and E.S. supervised the article.
The authors have no support to report.
The authors have no funding to report.
The authors have declared that no competing interests exist.